Each year, approximately four million Americans undergo cataract surgery — the most common surgical procedure in the United States. The U.S. remains the only developed country without an FDA-approved intracameral antibiotic for endophthalmitis prophylaxis, despite real-world evidence from millions of surgeries worldwide.
Cataract surgery is the most common surgical procedure in the United States, with the majority of cases performed on Medicare beneficiaries. Preventing post-operative endophthalmitis is paramount and currently depends on a complex multi-week topical antibiotic regimen — expensive, difficult for elderly patients to administer, and clinically inferior to intracameral injection.
A meta-analysis of 3,566,022 eyes demonstrates a 73% reduction in endophthalmitis odds with intracameral moxifloxacin. Yet no FDA-approved formulation exists in the U.S., forcing surgeons to rely on off-label compounding. The FDA's December 2025 RWE guidance opens approval pathways using the exact kind of macro-scale evidence already available.
Three coordinated actions — FDA evaluation under the RWE framework, CMS reimbursement pathway review, and VHA implementation — would unlock up to $8.7 billion in federal savings over ten years while protecting patients and standardizing care.
Cataract surgery is the most common surgical procedure in the United States. Preventing post-operative infection — endophthalmitis — is paramount and currently relies on complex multi-week topical antibiotic eyedrop regimens that are expensive, difficult for elderly patients to administer, and clinically inferior to modern alternatives.
Surgeons worldwide have adopted intracameral moxifloxacin: a single antibiotic injection delivered at the close of surgery. Yet no FDA-approved intracameral formulation currently exists in the United States. As a result, U.S. surgeons must rely on off-label compounding and dilution — introducing unnecessary safety risks, regulatory uncertainty, and avoidable cost.
A 2022 VA Evidence Synthesis Program meta-analysis pooled fourteen comparative studies covering 3,566,022 eyes and found that intracameral moxifloxacin reduced the odds of endophthalmitis by 73% compared with standard care (OR 0.27, 95% CI 0.19–0.40, p < .0001). Findings are remarkably stable across study designs, geographies, and surgery types.
| Source | Sample (eyes) | Finding |
|---|---|---|
| Aravind Eye Care System | 2,062,643 | 3.5-fold reduction in endophthalmitis |
| Kaiser Permanente (U.S.) | 315,246 | 72% reduction in infection risk |
| French national registry | ~6,000,000 | Sustained nationwide decline |
| VA ESP meta-analysis | 3,566,022 | 73% reduction (OR 0.27) |
A traditional Phase III clinical trial would require 40,000–60,000 patients, six to seven years, and an estimated $25 million to demonstrate statistical significance — despite millions of existing real-world cases already confirming safety and effectiveness. The FDA's December 2025 RWE guidance was built for exactly this kind of evidence base.
The current postoperative eyedrop regimen is costly and inefficient. A standardized intracameral injection delivers comparable or better outcomes at a fraction of the cost.
| Approach | Cost per eye | Federal impact |
|---|---|---|
| Traditional postoperative eyedrops | $103–$228 | Current baseline |
| Intracameral "dropless" injection | $16–$22 | Up to $450M annual savings |
| Endophthalmitis treatment (per case) | $5,000–$13,000 | Avoided via 73% risk reduction |
No new mandates. No new programs. Three targeted steps to unlock safety and savings benefits the existing evidence already supports.
Encourage the FDA to evaluate intracameral moxifloxacin using existing real-world evidence datasets under its December 2025 guidance.
Direct CMS to evaluate reimbursement pathways that allow adoption of dropless cataract surgery protocols, generating significant federal savings.
Support policy enabling standardized intracameral antibiotic access across the Veterans Health Administration to improve patient safety and reduce costs.
Real-world evidence from millions of surgeries demonstrates that intracameral moxifloxacin is safer, more effective, and far less expensive than the current eyedrop-based system. Approving a standardized formulation would protect patients, modernize surgical practice, and save billions in federal healthcare spending.
Share a few details and we'll follow up to schedule a briefing.